A time-honored strategy pharmaceutical companies use to keep brands alive after patent expiry is to combine one brand with another to create a combination pill. Pfizer, for example, has combined Lipitor and Norvasc to create Caduet.I suggest that Pfizer start thinking about its Viagra erectile dysfunction (ED) franchise. Viagra will go off patent as early as 2011.
One specific suggestion I have is to combine Viagra with Chantix (indicated for smoking cessation). I call this combination "ChanGra-La," which is pronounced virtually the same as Shangri-La, the mystical, harmonious, earthly paradise and utopia described in the novel Lost Horizon.
"What," you may ask, "could justify such a combination?"
Glad you asked!
According to an Italian study mentioned in a BMJ news item ("Erectile dysfunction may be an early sign of heart disease, suggests new research"), of 860 middle aged men, 40% of men who had erectile dysfunction (ED) smoked heavily, compared with 4% in the control group. Another study provided a link between ED and heart disease: "A pilot study by Greek researchers evaluated the incidence of asymptomatic coronary artery disease in 26 men with erectile dysfunction and found that nearly a quarter (23%) had coronary artery disease confirmed by angiography," reported BMJ.
In other words, if a pill like ChanGra-La can simultaneously help middle-aged men quit smoking AND obtain an erection, that therapy would have an extra-added benefit of preventing future heart attacks. A virtual "Shangri-La" for Pfizer!
There would be added benefits as well. Chantix, for example, has some notable "side effects," such as vivid "dreams" or hallucinations that may heighten a man's sexual experience. In fact, many dreams associated with Chantix are sexual in nature (see "Chantix Californication Dreamin': Viagra II"). This should not surprise anyone who knows that Chantix works by competing with nicotine to stimulate the brain's pleasure center.
One problem I foresee is that both Viagra and Chantix are not approved to be taken in daily doses or for a long period of time. Pfizer, however, should easily be able to find a work-around. After all, there is now a daily dosage form for Cialis, which competes with Viagra.
The Chantix portion of ChanGra-La is a bigger problem. It is recommended that Chantix be taken for only 12 weeks, whereas ChanGra-La would have to be taken indefinitely to be effective. I'm not sure how to get around this -- maybe have an alternating 12-week cycle of ChanGra-La with Chantix followed by a cycle of Chantix replaced by a placebo compound (eg, sugar), etc.
Obviously, such a regimen would require not just a pill, but also a support "program." Pfizer already has some related experience from its Chantix "GETQUIT Support Program." For ChanGra-La, I suggest a "GETHARD Support Program."
"But hasn't Pfizer recently announced it would no longer invest in cardiovascular drug research?," you might ask.
Yes it has. But the beauty of the ChanGra-La strategy is that it requires virtually no R&D, just a little trial at worst.
Approval by FDA should be a cinch. There's probably no middle-aged man out there who would not like to take ChanGra-La and since most FDA advisory committee members and reviewers are men...case closed!
There is a link between ED an cardiovasc. diseases - but there is absolutely no link between treatung ED and modifing CV-risk at the same time.
ReplyDeletewew, this review make me little confused about buying chantix :(
ReplyDelete